How to Start Medication for Tardive Dyskinesia
For established tardive dyskinesia, initiate treatment with a VMAT2 inhibitor—either valbenazine or deutetrabenazine—as these are the only FDA-approved, first-line medications with Level A evidence for treating TD. 1, 2, 3
Initial Assessment Before Starting Treatment
Before initiating any TD medication, you must:
- Confirm the diagnosis using the Abnormal Involuntary Movement Scale (AIMS) to establish baseline severity 4
- Document the severity and distribution of involuntary movements (orofacial, trunk, extremities)
- Review the causative medication regimen and determine if the dopamine receptor-blocking agent can be discontinued or switched 5
Treatment Algorithm
Step 1: Address the Causative Agent
If clinically feasible, discontinue the offending antipsychotic. This is the first-line management approach, as TD may improve or resolve with withdrawal of the dopamine-blocking medication 5. However, for most patients with serious mental illness (schizophrenia, bipolar disorder), stopping antipsychotics is not possible due to relapse risk.
If antipsychotic continuation is necessary, consider switching from a first-generation antipsychotic to a second-generation agent with lower D2 affinity—specifically clozapine or quetiapine—as this may reduce TD symptoms 5, 6. Atypical antipsychotics carry a lower risk of worsening TD compared to typical agents 7.
Step 2: Initiate VMAT2 Inhibitor Therapy
VMAT2 inhibitors are the only medications with robust evidence (Level A) and FDA approval specifically for TD treatment. 2, 3, 8
Valbenazine Initiation:
- Start with 40 mg once daily
- Titrate to 80 mg once daily after one week based on tolerability
- This is a once-daily medication, which may improve adherence 1
Deutetrabenazine Initiation:
- Start with 6 mg twice daily (12 mg total daily dose)
- Increase weekly by 6 mg/day increments
- Target dose typically 18-36 mg/day in divided doses
- Requires twice-daily dosing 1
Key differences to guide selection:
- Valbenazine has simpler once-daily dosing
- Deutetrabenazine requires more frequent titration and twice-daily administration
- Both have similar efficacy; choice depends on patient adherence patterns and tolerability 1
Step 3: Monitor Response
- Reassess AIMS scores at 4-8 weeks after reaching target dose 4
- Continue regular AIMS assessments every 3-6 months during treatment 9
- Adjust dose based on symptom improvement and adverse effects
- Common adverse effects include sedation, akathisia, and parkinsonism (monitor for these) 2
Alternative Approaches (Lower Evidence)
If VMAT2 inhibitors are unavailable, contraindicated, or ineffective, consider second-tier options with lower-level evidence 2:
- Clonazepam: May provide modest benefit
- Ginkgo biloba: Some evidence for efficacy
- Amantadine: Limited supporting data
Avoid anticholinergics (benztropine, trihexyphenidyl) as they do not treat TD and may worsen symptoms 7.
Critical Pitfalls to Avoid
Do not delay treatment. TD becomes increasingly irreversible with time, so early intervention is crucial 4
Do not increase the causative antipsychotic dose in an attempt to suppress TD movements—this worsens the underlying pathology 9
Do not use typical antipsychotics if switching is necessary, as they carry a 50% risk of TD after 2 years of continuous use in elderly patients 7
Ensure informed consent about TD risks before starting any dopamine-blocking medication, and document baseline AIMS 9
Monitor for depression and suicidality when using VMAT2 inhibitors, as these are potential adverse effects requiring vigilance 2
Special Considerations
For patients requiring continued antipsychotic therapy: VMAT2 inhibitors allow you to treat TD while maintaining psychiatric stability, as they do not directly block D2 receptors 10, 11. This represents a major advance over historical approaches.
For severe, treatment-resistant TD: Deep brain stimulation may be considered, though this remains a specialized intervention requiring referral 2.